662 adult acute myeloid leukemia (AML) cases characterized on the Affymetrix Human Genome U133 Plus 2.0 Microarray

ABSTRACT: The pretreatment karyotype of leukemic blasts is currently the key determinant in therapy decision-making in acute myeloid leukemia (AML). However, approximately fifty percent of AML patients, often carrying a normal karyotype, are currently unclassifiable based these established methods. Gene expression profiling has proven to be valuable for risk stratification of AML. This is a repository of 662 adult AML cases characterized on gene expression microarrays and used for different studies investigating the mechanisms underlying leukemogenesis. Bone marrow aspirates or peripheral blood samples of three independent representative cohorts of de novo AML patients, comprising 277, 256 and 129 cases respectively, were collected at diagnosis. Gene expression profiling was performed on 662 adul

ORGANISM(S): Homo sapiens

SUBMITTER: Peter Valk 

PROVIDER: E-MTAB-3444 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress